Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
36.70 -0.14 (-0.38%) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 36.65 -0.05 (-0.14%) 17:27 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
36.25
Day High
36.94
Open 36.78
Previous Close 36.84 36.84
Volume 1,259,500 1,259,500
Avg Vol 2,773,000 2,773,000
Stochastic %K 21.59% 21.59%
Weighted Alpha +57.46 +57.46
5-Day Change -0.26 (-0.70%) -0.26 (-0.70%)
52-Week Range 20.14 - 40.02 20.14 - 40.02
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,271,633
  • Shares Outstanding, K 279,881
  • Annual Sales, $ 2,169 M
  • Annual Income, $ 521,270 K
  • EBIT $ 605 M
  • EBITDA $ 633 M
  • 60-Month Beta 0.57
  • Price/Sales 4.75
  • Price/Cash Flow 19.13
  • Price/Book 4.69

Options Overview Details

View History
  • Implied Volatility 39.30% ( +3.91%)
  • Historical Volatility 29.82%
  • IV Percentile 37%
  • IV Rank 38.63%
  • IV High 72.42% on 08/05/24
  • IV Low 18.44% on 11/08/24
  • Put/Call Vol Ratio 1.04
  • Today's Volume 1,115
  • Volume Avg (30-Day) 1,413
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 36,506
  • Open Int (30-Day) 39,262

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.34
  • Number of Estimates 7
  • High Estimate 0.42
  • Low Estimate 0.27
  • Prior Year 0.12
  • Growth Rate Est. (year over year) +183.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.07 +1.75%
on 03/18/25
Period Open: 38.69
40.02 -8.30%
on 03/10/25
-1.99 (-5.14%)
since 02/28/25
3-Month
31.90 +15.05%
on 01/24/25
Period Open: 33.81
40.02 -8.30%
on 03/10/25
+2.89 (+8.55%)
since 12/27/24
52-Week
20.14 +82.22%
on 05/29/24
Period Open: 23.73
40.02 -8.30%
on 03/10/25
+12.97 (+54.66%)
since 03/28/24

Most Recent Stories

More News
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib).The regulatory body approved Cabometyx for the treatment of adult and pediatric patients...

BAYRY : 6.1435 (+0.06%)
NVO : 69.30 (-1.23%)
EXEL : 36.70 (-0.38%)
BMY : 60.02 (+1.90%)
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe. The company's...

MRK : 89.23 (+1.86%)
EXEL : 36.70 (-0.38%)
BMY : 60.02 (+1.90%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.6000 (-2.31%)
EXEL : 36.70 (-0.38%)
ONC.TO : 0.85 (-5.56%)
ALXO : 0.6551 (-8.27%)
CRDF : 3.29 (-4.36%)
VSTM : 6.19 (-8.02%)
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

For Immediate ReleaseChicago, IL – February 26, 2025 – Stocks in this week’s article are Gilead Sciences GILD, Exelixis EXEL, Synchrony Financial SYF and Molson Coors TAP.4 PEG-Based GARP Stocks...

SYF : 52.43 (-3.19%)
TAP : 60.53 (-0.71%)
EXEL : 36.70 (-0.38%)
GILD : 111.79 (+0.57%)
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not only...

SYF : 52.43 (-3.19%)
TAP : 60.53 (-0.71%)
EXEL : 36.70 (-0.38%)
GILD : 111.79 (+0.57%)
Why Exelixis Stock Trounced the Market on Thursday

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push...

EXEL : 36.70 (-0.38%)
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

GRAL : 26.93 (-5.77%)
ADMA : 20.26 (-0.10%)
EXEL : 36.70 (-0.38%)
GLYC : 0.2182 (-10.68%)
MBRX : 1.0400 (-0.95%)
Exelixis (EXEL) Q4 2024 Earnings Call Transcript

EXEL earnings call for the period ending December 31, 2024.

EXEL : 36.70 (-0.38%)
Exelixis Posts 63.7% Profit Surge

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.

EXEL : 36.70 (-0.38%)
Exelixis: Q4 Earnings Snapshot

Exelixis: Q4 Earnings Snapshot

EXEL : 36.70 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 37.70
2nd Resistance Point 37.32
1st Resistance Point 37.01
Last Price 36.70
1st Support Level 36.32
2nd Support Level 35.94
3rd Support Level 35.63

See More

52-Week High 40.02
Last Price 36.70
Fibonacci 61.8% 32.43
Fibonacci 50% 30.08
Fibonacci 38.2% 27.73
52-Week Low 20.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies